Inhibition of Antigen-specific T Cell Trafficking into the Central Nervous System Via Blocking PECAM1/CD31 Molecule
Overview
Affiliations
Trafficking of antigen-specific T cells into the central nervous system (CNS) is an important initiating step in inflammation in the brain. In spite of the extensive knowledge about the role of adhesion molecules in T cell migration across peripheral vessels, the mechanism of the entry of antigen-specific T cells into the CNS is not known. This work was designed to study the regulatory roles of adhesion molecules in antigen-specific T cell migration into the CNS. Antigen-specific T cells were tracked in an in vivo migration assay using T cell receptor (TCR) transgenic mice having 95% of T cells specific for a defined antigen. pigeon cytochrome c (PCC). TCR transgenic mice were cannulated intraventricularly (IVT) for PCC antigen infusion and cerebrospinal fluid (CSF) sampling. Upon PCC infusion into the CNS, the number of alpha/beta TCR+ Vbeta3+ Mac1- cells in the CSF was characterized in the presence or absence of anti-adhesion molecule reagents. We found that antibodies against VCAM-1 (CD106), VLA-4 (CD49d/CD29), ICAM-1 (CD54), and LFA-1 (CD11a/CD18) did not influence the increased number of antigen-specific T cells in the CSF However, upon intravenous (i.v.) injection, anti-PECAM-1 (CD31) antibody or PECAM-Ig chimeric molecule inhibited the trafficking of alpha/beta TCR+ Vbeta3+ Mac1- cells into the CNS. The expression of PECAM-1 (CD31) was also up-regulated on antigen-specific T cells in a time-dependent manner in vitro upon antigenic stimulation. The antigen-induced activation of T cells in vivo was measured by CD44 and LFA-1 expression and found to be comparable between mPECAMIg-treated mice and wild-type serum control-treated groups. This indicates that CD31 inhibition of antigen-specific T cell accumulation in the CNS is probably not due to a functional inhibition of these cells. Finally, adoptive transfer of CFSE-labeled AND transgenic cells into naïve animals resulted in the accumulation of these cells in the CNS upon PCC IVT immunization that was also inhibited by mPECAMIg treatment. Hence, PECAM-1 (CD31) might play an important role in regulating antigen-specific T cells trafficking in CNS inflammatory diseases.
Bury L, Falcinelli E, Mezzasoma A, Guglielmini G, Momi S, Gresele P Haematologica. 2021; 107(7):1643-1654.
PMID: 34407603 PMC: 9244828. DOI: 10.3324/haematol.2021.278776.
Liu Y, Zhang Z, Li W, Tian S Front Cell Dev Biol. 2021; 8:593653.
PMID: 33425898 PMC: 7786183. DOI: 10.3389/fcell.2020.593653.
Surzenko N, Pjetri E, Munson C, Friday W, Hauser J, Mitchell E PLoS One. 2020; 15(7):e0223395.
PMID: 32645024 PMC: 7347133. DOI: 10.1371/journal.pone.0223395.
Fang Y, Tian Y, Huang Q, Wan Y, Xu L, Wang W J Neuroinflammation. 2019; 16(1):96.
PMID: 31072336 PMC: 6506965. DOI: 10.1186/s12974-019-1485-5.
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Malhotra S, Villar L, Costa C, Midaglia L, Cubedo M, Medina S J Neuroinflammation. 2018; 15(1):296.
PMID: 30367633 PMC: 6202809. DOI: 10.1186/s12974-018-1336-9.